What are the major toxicities of methotrexate and how should they be monitored?

Methotrexate Toxicities and Monitoring

The three major life-threatening toxicities of methotrexate are myelosuppression (most common cause of fatality), pulmonary fibrosis, and hepatotoxicity, with myelosuppression accounting for approximately 41% of methotrexate-associated deaths. 1

Major Toxicities

Life-Threatening Toxicities

Myelosuppression is the leading cause of methotrexate-related mortality:

• Accounts for 67 of 164 (41%) methotrexate-associated fatalities 1
• Can occur after even a single dose of methotrexate 1, 2
• Pancytopenia may develop as late as 4-6 weeks after dose increases 1, 2
• Risk is highest in patients with renal insufficiency, advanced age, lack of folate supplementation, drug interactions (especially sulfonamides), hypoalbuminemia, and dosing errors 1, 2

Pulmonary fibrosis is the second most fatal complication:

• Responsible for 30 of 164 (18%) methotrexate-associated deaths 1
• Must be ruled out in any patient presenting with new cough or respiratory symptoms 1
• Notably less common in psoriasis patients compared to rheumatoid arthritis patients 1, 2
• A systematic review found methotrexate was not associated with significantly increased respiratory infections (RR 1.03,95% CI 0.90-1.17) 2

Hepatotoxicity causes fewer deaths but requires vigilant monitoring:

• Accounts for 8 of 164 (5%) methotrexate-associated fatalities 1
• Risk is particularly elevated in psoriasis patients compared to rheumatoid arthritis patients 2
• High cumulative doses increase liver damage risk 2

Common Minor Toxicities

These occur shortly after initiation and include 1, 2:

• Nausea and anorexia
• Stomatitis (mouth ulcers)
• Fatigue
• Hair loss (rare) 2

These can be mitigated by: switching from oral to subcutaneous/intramuscular administration, splitting the weekly dose over 24 hours, taking with food or at bedtime, or increasing folate supplementation 1, 2

Infectious and Malignancy Risks

Due to immunosuppression, methotrexate increases risk of 2:

• Reactivation of latent tuberculosis
• Hepatitis B and C reactivation
• Epstein-Barr virus-associated B-cell lymphoma
• Non-Hodgkin's lymphoma (may regress upon methotrexate discontinuation) 3

Risk Factors for Major Toxicities

Hematologic Toxicity Risk Factors 1, 2:

• Renal insufficiency (most important)
• Advanced age
• Lack of folate supplementation
• Methotrexate dosing errors
• Drug interactions (especially NSAIDs, sulfonamides, penicillins, trimethoprim/sulfamethoxazole)
• Hypoalbuminemia
• Greater than moderate alcohol intake

Hepatotoxicity Risk Factors 1, 2:

• History of or current greater than moderate alcohol consumption (>1 drink/day for women, >2 drinks/day for men)
• Persistent abnormal liver chemistry findings
• History of liver disease including chronic hepatitis B or C
• Family history of inheritable liver disease
• Diabetes mellitus
• Obesity (BMI ≥40 kg/m²)
• History of significant exposure to hepatotoxic drugs or chemicals
• Hyperlipidemia
• Nonalcoholic steatohepatitis (common psoriasis comorbidity)

Monitoring Protocol

Baseline Assessment 2, 4, 3:

• Complete blood count (CBC) with differential and platelet count
• Liver function tests (AST, ALT, alkaline phosphatase, albumin, bilirubin)
• Renal function (serum creatinine, calculated GFR)
• Hepatitis B and C serologic studies
• Tuberculosis testing (PPD, T-Spot, or QuantiFERON Gold) based on risk factors
• Chest X-ray (within previous year)
• Pregnancy test for women of childbearing age
• Noninvasive liver fibrosis assessment (FIB-4, Fibrosure, Fibrometer, or Hepascore) 2
• Consider HIV serology in at-risk patients 5

Baseline liver biopsy is NOT recommended regardless of risk factors 2

Ongoing Monitoring

For patients WITHOUT hepatotoxicity risk factors 2:

• CBC and liver function tests every 3-6 months (assuming no abnormalities)
• More frequent monitoring (every 7-14 days) for the first month 5
• Repeat noninvasive liver fibrosis serology annually 2
• After 3.5-4.0 g cumulative dose, consider GI consultation and/or vibration-controlled transient elastography 2

For patients WITH hepatotoxicity risk factors 2:

• Same monitoring frequency as low-risk patients
• Annual GI/hepatology consultation or vibration-controlled transient elastography regardless of cumulative dose 2

After dose increases 1, 2:

• More frequent monitoring is essential as pancytopenia can occur up to 6 weeks after dose escalation

When to Refer or Perform Liver Biopsy 2, 6:

• Persistent elevation in liver enzymes (5 of 9 determinations above normal in 12 months, or 6 of 12 if monthly testing) 6
• Decline in serum albumin below normal range in a patient with normal nutritional status 2
• Noninvasive serology consistent with greater than minimal fibrosis 2
• Elevations <3-fold upper limit of normal: repeat in 2-4 weeks 2

Essential Preventive Measures

Folate Supplementation

Folic acid supplementation (1-5 mg daily, except on methotrexate day) is strongly recommended for all patients 1, 2:

• Reduces gastrointestinal and hepatic adverse effects 2
• Reduces hematologic toxicity 1
• Very high doses (>5 mg daily) may slightly reduce methotrexate efficacy, though this is debated 1
• If toxicity develops despite folate, increase the folate dose 1

Test Dose Consideration

A test dose (2.5-5 mg) should be considered, especially in patients with impaired kidney function 1, 2, 1:

• CBC checked 5-6 days after test dose to ensure no myelosuppression 1
• Does not guarantee prevention of pancytopenia but is mandatory in high-risk patients 1

Drug Interactions to Avoid 3:

• NSAIDs with high-dose methotrexate: can elevate and prolong methotrexate levels, causing fatal hematologic and GI toxicity 3
• Sulfonamides: reduce tubular secretion, enhance toxicity 3
• Penicillins: reduce renal clearance, increase toxicity 3
• Trimethoprim/sulfamethoxazole: increases bone marrow suppression 3
• Probenecid: diminishes renal tubular transport 3
• Nitrous oxide anesthesia: potentiates folate-dependent toxicity; avoid concurrent use 3

Contraindications

Absolute Contraindications 2, 3:

• Pregnancy (Category X - causes embryotoxicity, abortion, and fetal defects)
• Breastfeeding
• Cirrhosis
• Significant thrombocytopenia, leukopenia, or anemia

Relative Contraindications 2:

• Concomitant sulfa drugs or acitretin (may be used with appropriate hepatic monitoring)

Women of childbearing age must use effective contraception and wait at least 3 months after discontinuation before attempting pregnancy 2, 3

Critical Clinical Pitfalls

The most dangerous error is daily dosing instead of weekly dosing - this has led to fatal toxicity 3. Prescriptions should never be written on a PRN basis, and both physician and pharmacist must emphasize weekly dosing to patients 3.

Patients must seek urgent medical attention for 5:

• Fever or flu-like illness
• Mouth ulceration
• Unexplained tiredness
• Unexplained bruising or bleeding gums
• Nausea, vomiting, abdominal pain, or dark urine
• New breathlessness or cough